No Data
wai yuen tong (00897): Xue Yongheng has been appointed as the Chairman of the Remuneration Committee.
Wai Yuen Tong (00897) announced that Mr. Siu Man-ho hopes to focus more on his own business activities, so Mr. Siu has resigned...
The first batch of pharmaceutical fund's third quarter report is released! Shareholding in US stocks reduced, while increasing holdings in Hong Kong stocks and A-shares.
The first batch of fund managers exposed in the third quarter medical investment strategy, significantly increased the proportion of innovative drugs, especially the position of Hong Kong-listed innovative drugs with greater flexibility.
Express News | China Securities Co.,Ltd.: Focus on investment opportunities in seven directions in the health care industry.
The Hong Kong government today established a task force on the development of traditional Chinese medicine.
The Hong Kong SAR Government announced that in order to more widely absorb opinions in the process of formulating the "Traditional Chinese Medicine Development Blueprint", the Traditional Chinese Medicine Development Blueprint Subcommittee was established under the Chinese Medicine Development Committee today. The relevant blueprint subcommittee will propose suggestions to the Development Committee on specific overall development strategies for traditional Chinese medicine, as well as short-term, medium-term, and long-term goals and feasible plans for long-term planning. The subcommittee will set up different working groups to focus on discussions on different topics. The Commissioner for the Development of Chinese Medicine of the Department of Health will serve as the chairman of the blueprint subcommittee, and the members will cover different stakeholders in the traditional Chinese medicine and related sectors, in order to establish a comprehensive"blue".
Morgan Stanley Fund: Will the pharmaceutical stocks "counterattack" as the Federal Reserve cuts interest rates?
Morgan Stanley Fund said that if the Federal Reserve cuts interest rates, risk appetite for funds may increase, and innovative drugs with higher growth potential may receive more risk capital favor in the short to medium term, gaining some upward momentum.
It is reported that Yunnan plans to establish a fund for the development of traditional Chinese medicine materials industry.
According to reports from domestic media, Yunnan Province has formulated a three-year action plan and regional planting plan for the production of traditional Chinese medicine materials, and relevant departments have set up a fund for the development of traditional Chinese medicine industry, led by Yunnan Baiyao Group. Yunnan will also support Yunnan Baiyao Group to lead the industry and promote its development, making it a leading enterprise in Yunnan's traditional Chinese medicine industry and driving the development of other enterprises.
No Data
No Data